Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Pharmacology Study of MT-3921 in Healthy Adult Males
jRCT2031220182Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute cervical spinal cord injury (ACSCI) and HTLV-1-associated myelopathy (HAM) comparing MT-3921 IV with Placebo IV (2 arms). Started Aug 2022; status: completed.
02
Drugs
unasnemab
03
Conditions
acute cervical spinal cord injury (ACSCI)HTLV-1-associated myelopathy (HAM)
Beyond the preview
Go deeper on jRCT2031220182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220182.